INDIA—Zydus Lifesciences Ltd has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company to market the novel Potassium Competitive Acid Blocker (P-CAB), Vonoprazan, in India. 

Under the terms of this agreement, Zydus will be marketing the drug for the treatment of gastroesophageal reflux disease (GERD) under the brand name Vault in India. 

Speaking on this development, Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Ltd., emphasized the company’s rich legacy in marketing gastrointestinal therapies in India.

He noted that Zydus has been offering breakthrough clinical options across the spectrum of gastrointestinal treatments.  

Dr. Patel highlighted that, in keeping with their patient-centric approach, Zydus has been enabling access to newer treatment options and innovative healthcare solutions for nearly three decades.  

He expressed his excitement about adding Vault to their wide basket of gastro therapeutic products, thereby expanding their range of treatments for acid peptic disorders. 

Gastroesophageal Reflux Disease (GERD) is a prevalent condition affecting a significant number of patients in India.  

As a pioneer in providing innovative treatment options to manage GERD, Zydus has introduced various products such as Pantodac (Pantoprazole), Happi (Rabeprazole), and Ocid (Omeprazole).  

Remarkably, Zydus was the first company to introduce Pantoprazole in India in 1999, marking a significant milestone in the treatment of GERD. 

 The launch of Vault will provide clinicians with a novel treatment option to manage GERD and other acid peptic disorders for the Indian population.  

This new addition to Zydus’s portfolio underscores their commitment to offering advanced therapeutic solutions for acid peptic disorders. 

 The release added that Vault is expected to significantly enhance the treatment landscape for GERD, providing a much-needed alternative for patients. 

 Dr. Patel also mentioned that the introduction of Vault  aligns with Zydus’s mission to offer innovative and effective treatment options.  

By expanding their product range, Zydus aims to address the unmet needs of patients suffering from GERD and other related conditions.  

This new drug is expected to improve patient outcomes and provide a reliable alternative to existing therapies. 

Sign up to receive our email newsletters  with  latest news updates and  insights from Africa and the World HERE